SIETES :: 92826 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

2.

Taylor P. J&J hit by $8bn judgment for man claiming breast growth due to Risperdal. PMLiVE 2019:9 de octubre. [Ref.ID 103192]

3.

Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]

4.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 2019:30 de julio. [Ref.ID 103183]

5.

Anderson TS, Jing B, Auerbach A, Wray CM, Lee S, Boscardin WJ, Fung K, Ngo S, Silvestrini M, Steinman MA. Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103182]

6.

Sainato M. Las farmacéuticas disparan el precio de la insulina y obligan a los estadounidenses a escoger entre techo o medicamentos . eldiario.es 2019:24 de septiembre. [Ref.ID 103180]

7.

Vélez AM. La dueña del monopolio del opio en España oculta los sueldos de su cúpula tras la salida del multimillonario Abelló . eldiario.es 2019:11 de septiembre. [Ref.ID 103173]

8.

Khan R, Nugent CM, Scaffidi MA, Gimpaya N, Grover SC. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med 2019;179:8 de julio. [Ref.ID 103170]

9.

Dyer O. Industry payments to doctors drive surge in gabapentinoid prescribing, study finds. BMJ 2019;366:19 de julio. [Ref.ID 103169]

10.

Anónimo. Hepatitis C medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to rare occurrence of serious liver injury in some patients with advanced liver disease. FDA MedWatch alert 2019:28 de agosto. [Ref.ID 103166]

11.

Beddoes ZM. Johnson & Johnson, Purdue and other opioid-peddlers face a reckoning. The Economist 2019:1. [Ref.ID 103165]

12.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]

13.

Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]

14.

Taylor P. Ex-FDA chief Gottlieb's quick move to pharma raises eyebrows. PMLiVE 2019:28 de junio. [Ref.ID 103148]

15.

Xie Y, Bowe B, Yan Y, Xian H, Li T. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:30 de mayo. [Ref.ID 103138]

16.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie MA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92:5 de marzo. [Ref.ID 103132]

17.

Healy D. EMA acknowledges persistent sexual dysfunction after SSRIs & SNRIs. Rxisk 20019:11 de junio. [Ref.ID 103130]

18.

Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]

19.

Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. Ann Intern Med 2019:7 de mayo. [Ref.ID 103117]

20.

Pinto T. Las farmacéuticas se apoyan en EEUU y Alemania para frenar en la OMS un plan que haga más transparente el precio de la medicinas. eldiario.es 2019:15 de mayo. [Ref.ID 103116]